Latest Infectious Disease News
WEDNESDAY, Dec. 28 (HealthDay News) -- World Health Organization researchers are reporting an apparent spike in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug.
"In 2007/2008, a different A(H1N1) influenza virus developed Tamiflu-resistance," explained WHO research scientist Aeron C. Hurt, who reported the spike. "On that occasion, it was first detected in large numbers in Europe. However, within 12 months the virus had spread globally, such that virtually every A(H1N1) virus around the world was resistant to this drug," he explained.
"This previous situation demonstrated the speed and potential for a Tamiflu-resistant virus to spread worldwide," Hurt added. "Our concern is that this current pandemic 2009 A(H1N1) Tamiflu-resistant virus may also spread globally."
Hurt, who is based in the Collaborating Centre for Reference and Research on Influenza in North Melbourne, outlined his observations in the Dec. 29 issue of the New England Journal of Medicine.
To explore the question of H1N1-drug resistance, Hurt and his team obtained viral samples from 182 H1N1 flu patients (aged from one month to 74 years) who were being cared for either in an emergency department or an intensive care unit, or by their general practitioner, during the recent winter in Australia.
Subsequent lab tests revealed that it would take more than 500 times the concentration of Tamiflu usually prescribed for nonresistant flu strains just to cut key aspects of resistant viral activity in half.
Five of the resistant patients were under the age of 5 years. Only one of the patients had been treated with Tamiflu prior to viral sampling, while three had previously been vaccinated with the 2011 influenza vaccine.
The team noted that July marked the high point of resistant cases, most of which were found within a 30-mile or so radius of Australia's seventh-largest urban center, Newcastle. A handful were located in Sydney, the country's largest city.
Raising concerns about the ease of transmission, the investigators noted that some of the resistant cases involved related patients: in four households, two family members had been diagnosed with resistant H1N1. In two other cases, the patients were linked simply by having shared a short car ride.
Hurt pointed out that the resistant strain does not appear to cause more serious illness than "normal" strains, and that no one has died as a result. But he did suggest that the very real prospect that such resistant strains could spread far beyond the shores of Australia is alarming.
"Tamiflu is widely used in the U.S.A. and other parts of the world such as Japan," he noted. "If the virus spreads widely, then there is potential that patients will be treated with a drug that will have little or no benefit. The biggest impact may be in individuals, such as the elderly or immune-compromised, who have a higher risk of complications from influenza infection and most commonly benefit from early and effective antiviral treatment."
Dr. Len Horovitz, a pulmonary specialist with North Shore-LIJ/Lenox Hill Hospital in New York City, explained that, although other non-Tamiflu treatments remain effective, the advent of resistant flu strains can waste valuable time.
"Flu medications have to be given within 24 to 48 hours of the onset of symptoms or they do no good," he said. "So this is a real problem, because we live in a global village. People will get on a plane in Australia and come to my office. This will not be isolated to one part of the world," he added.
"So what I tell people is that immunization is paramount," Horovitz said. "It's important that anybody over the age of 6 months get vaccinated, and that includes pregnant women for whom there is a mercury-free vaccine. If we all did this, we would have very low levels of flu. People wouldn't get it to begin with. And then we wouldn't have to worry whether the drugs we have work or not."
Copyright © 2011 HealthDay. All rights reserved.
Health Solutions From Our Sponsors